Cargando…
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545538/ https://www.ncbi.nlm.nih.gov/pubmed/33102473 http://dx.doi.org/10.3389/fcell.2020.562522 |